BRIEF published on 02/11/2026 at 22:35, 1 month 14 days ago Integrated BioPharma Announces Q4 2025 Financial Results Financial Results Revenue Decline Net Loss Operating Loss Customer Dependency
PRESS RELEASE published on 02/11/2026 at 22:30, 1 month 14 days ago Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025 Integrated BioPharma, Inc. reports financial results for Q4 2025, showing a $1.3M decrease in revenue and operating loss compared to Q4 2024. Key financial details provided Financial Results Revenue Decrease Operating Loss Integrated BioPharma Quarterly Performance
BRIEF published on 11/10/2025 at 21:55, 4 months 15 days ago Integrated BioPharma Reports Financial Results for Q3 2025 Financial Results Net Income Revenue Decline Operating Income Contract Manufacturing
PRESS RELEASE published on 11/10/2025 at 21:50, 4 months 15 days ago Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025 Integrated BioPharma, Inc. reports financial results for the quarter ended September 30, 2025, with $12.7 million revenue and insights on operating income and net income Financial Results Revenue Net Income Operating Income Integrated BioPharma
BRIEF published on 09/23/2025 at 21:45, 6 months 2 days ago Integrated BioPharma Reports Fiscal Year 2025 Results Financial Results Revenue Growth Net Income Operating Income Contract Manufacturing
PRESS RELEASE published on 09/23/2025 at 21:40, 6 months 2 days ago Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2025 Integrated BioPharma, Inc. reports 11.8% increase in revenue for Q2 2025. Operating income rises in Q2 & FY 2025. Net loss in Q2 but net income grows for FY 2025 Revenue Increase Net Income Net Loss Operating Income Integrated BioPharma
BRIEF published on 05/14/2025 at 21:35, 10 months 11 days ago Integrated BioPharma, Inc. Posts Financial Results for Q1 2025 Financial Results Revenue Growth Operating Income Q1 2025 Key Customers
PRESS RELEASE published on 05/14/2025 at 21:30, 10 months 11 days ago Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025 Integrated BioPharma, Inc. reports a 6.1% revenue increase for Q1 2025 compared to Q1 2024. Company had operating income and net income growth. Key focus on core business and expanding customer base Financial Results Revenue Increase Net Income Operating Income Integrated BioPharma
BRIEF published on 02/13/2025 at 22:00, 1 year 1 month ago Integrated BioPharma Reports Quarterly Results with Increased Revenue Revenue Growth Q4 Results Operating Income Customer Base Expansion Integrated BioPharma
PRESS RELEASE published on 02/13/2025 at 21:55, 1 year 1 month ago Integrated BioPharma Reports Results for its Quarter Ended December 31, 2024 Integrated BioPharma, Inc. reports 9.6% increase in revenue to $12.6 million for quarter ended Dec 31, 2024. Operating income of $0.2 million. Detailed financial results provided Financial Results Revenue Increase Quarterly Report Operating Income Integrated BioPharma
Published on 03/26/2026 at 11:07, 46 minutes ago U.S. Mined and Refined Metals as well as Rare Earth Elements to Be Tokenized in Historic American Strategic Minerals and Datavault AI Deal
Published on 03/26/2026 at 11:00, 53 minutes ago Stagwell Expands the Harris Poll's Harrisquest Across Europe
Published on 03/26/2026 at 08:05, 3 hours 48 minutes ago Vanta Announces U.S. Ticker Symbol Change to VNTXF
Published on 03/26/2026 at 04:55, 6 hours 58 minutes ago Vanta Announces Capital Markets Initiatives to Strengthen Financial Position and Support Growth Initiatives
Published on 03/26/2026 at 11:03, 50 minutes ago EQS-Adhoc: VIDINEXT AG: Marketing agreement with Telekom Deutschland GmbH
Published on 03/26/2026 at 11:00, 52 minutes ago Genel Energy PLC: Posting of Annual Report and Notice of AGM
Published on 03/26/2026 at 11:00, 53 minutes ago Genel Energy PLC: Report on payments to governments for the year 2025
Published on 03/26/2026 at 11:00, 53 minutes ago ABB Ltd: ABB share buybacks - March 19, 2026 - March 25, 2026
Published on 03/26/2026 at 11:00, 53 minutes ago Independent study reveals 44% ROI with EQS Compliance Cockpit and payback in under six months
Published on 03/26/2026 at 07:30, 4 hours 23 minutes ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/25/2026 at 18:31, 17 hours 21 minutes ago Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 17:45, 18 hours 8 minutes ago Combined General Meeting on May 05, 2026: publication of the notice of Meeting
